How India Exports Colchicine to the World

In the United States, colchicine is approved for the treatment of gout and familial Mediterranean fever. The FDA approved the New Drug Application (NDA) for Colcrys (colchicine, USP) tablets 0.6 mg on July 30, 2009. Subsequently, the FDA granted orphan drug designation to colchicine for the treatment of familial Mediterranean fever on September 25, 2007, with marketing approval on July 29, 2009. The exclusivity period for this indication ended on July 29, 2016.

The FDA has also approved generic versions of colchicine. For instance, Zydus Pharmaceuticals (USA) Inc. received approval for Colchicine Tablets USP, 0.3 mg, on July 19, 2019. As of March 2026, there are multiple approved Abbreviated New Drug Applications (ANDAs) for colchicine, indicating a competitive market landscape.

Given that 64.9% of India's colchicine exports are directed to the United States, it is imperative for Indian exporters to ensure compliance with FDA regulations, including adherence to Good Manufacturing Practices (GMP) and bioequivalence requirements.

In the European Union, colchicine is subject to marketing authorization by national competent authorities. The European Medicines Agency (EMA) has issued product-specific bioequivalence guidance for colchicine tablets (0.5 mg and 1 mg), with the latest revision effective January 1, 2026. (ema.europa.eu) This guidance outlines the requirements for demonstrating bioequivalence, which is crucial for the approval of generic formulations.

The EMA also conducts periodic safety update report single assessments (PSUSAs) for colchicine. The most recent assessment, procedure number PSUSA/00000858/202307, resulted in a maintenance outcome, indicating no significant changes to the product's safety profile as of July 2023. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization of medicinal products, including colchicine. Post-Brexit, the UK has established its own regulatory framework, and Indian exporters must ensure compliance with MHRA requirements to access the UK market.

Colchicine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The inclusion in the list signifies that colchicine is considered essential for addressing key health needs.

Regarding pharmacopoeial standards, colchicine is monographed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards is essential for ensuring the quality and efficacy of colchicine products in various markets.

In India, colchicine is classified as a Schedule H drug under the Drugs and Cosmetics Act, 1940, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, colchicine is not listed under the Drugs (Prices Control) Order (DPCO), and thus, its price is not subject to government-mandated ceilings.

For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) and ensure compliance with the importing country's regulatory requirements.

The primary patent for Colcrys (colchicine) expired on July 29, 2016, ending the exclusivity period for the treatment of familial Mediterranean fever. This expiration has led to increased generic competition in the market, providing opportunities for Indian exporters to supply colchicine to various countries.

In April 2025, the FDA granted orphan drug designation to colchicine for the treatment of pericarditis, indicating ongoing interest in expanding its therapeutic applications.

In July 2025, the EMA adopted a revised product-specific bioequivalence guidance for colchicine tablets, effective January 1, 2026, reflecting updated regulatory expectations for generic formulations. (ema.europa.eu)

In July 2023, the EMA completed a periodic safety update report single assessment (PSUSA/00000858/202307) for colchicine, resulting in a maintenance outcome, indicating no significant changes to the product's safety profile. (ema.europa.eu)

These developments highlight the dynamic regulatory environment surrounding colchicine, emphasizing the need for exporters to stay informed and compliant with evolving standards.

Colchicine, a critical pharmaceutical compound, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70% of India's APIs are imported from China, underscoring a significant supply chain vulnerability.

The reliance on Chinese KSMs has led to supply disruptions in the past. For instance, in 2024, environmental regulatory actions in China resulted in the shutdown of numerous chemical factories, causing a substantial increase in the prices of essential KSMs. This, in turn, escalated the production costs for Indian pharmaceutical manufacturers. Such incidents highlight the risks associated with over-dependence on a single country for critical raw materials.

The export market for Colchicine from India is notably concentrated. The top five exporters account for 71.0% of the total export value, with ALKEM LABORATORIES LIMITED alone contributing 40.8%. This high concentration poses a single-source risk, where disruptions affecting these key players could significantly impact global supply.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in 2024, aiming to bolster domestic API and KSM production. By October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, the effectiveness of this initiative in diversifying the supplier base for Colchicine remains to be fully realized.

Geopolitical tensions have further complicated the Colchicine supply chain. In March 2026, military escalations in the Strait of Hormuz disrupted maritime traffic, leading to increased freight rates and insurance premiums. Given that a significant portion of global trade passes through this corridor, such disruptions can delay shipments and elevate costs for pharmaceutical exports.

Additionally, the ongoing U.S.-China trade tensions have introduced uncertainties in the pharmaceutical sector. In 2025, the U.S. Food and Drug Administration (FDA) issued alerts regarding potential shortages of certain drugs due to supply chain disruptions linked to these geopolitical issues. While Colchicine was not specifically mentioned, the situation underscores the broader risks affecting pharmaceutical supply chains.

• Diversify Raw Material Sources: Encourage Indian manufacturers to source KSMs from multiple countries to reduce dependency on China.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme to enhance local manufacturing capabilities for APIs and KSMs.

• Enhance Supplier Base: Promote the growth of small and medium-sized enterprises in the pharmaceutical sector to reduce market concentration.

• Develop Contingency Plans: Establish strategic reserves of critical APIs and KSMs to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Stay informed about international tensions and their potential impact on shipping routes and trade policies.

RISK_LEVEL: MEDIUM